Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Chang, Mark
Song, Alexander
Deyo, Logan James
Stamos, Daniel
Bloomer, Chance H.
Khoury, Lara M.
Porosnicu, Mercedes
机构：
[1] Atrium Hlth Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[2] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6062
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Genomic characteristics and immunotherapy outcomes in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
    Park, J. C.
    Cortes, M. Useche
    Durbeck, J.
    Clark, J. R.
    Zhao, Y.
    Saladi, S. V.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S856 - S856
  • [22] Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance
    Chen, Shu-Wei
    Li, Si-Hao
    Shi, Ding-Bo
    Jiang, Wen-Mei
    Song, Ming
    Yang, An-Kui
    Li, Yu-Dong
    Bei, Jin-Xin
    Chen, Wen-Kuan
    Zhang, Quan
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2019, 34 (04): : 398 - 405
  • [23] Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Haddad, Robert, I
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 982 - 984
  • [24] Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients
    Li, Lu
    Chen, Lu
    Yan, Lu
    Guo, Yueqian
    Li, Fang
    Fan, Ming
    Lan, Mei
    Lai, Xin
    Zhou, Jie
    Huang, Yecai
    Xu, Peng
    Lang, Jinyi
    Feng, Mei
    [J]. RADIATION ONCOLOGY, 2023, 18 (01)
  • [25] CYTOTOXIC REVIVAL IS IMPLICATED IN RESPONSE TO NEOADJUVANT PD-1 BLOCKADE FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Afeyan, Alexander
    Oliveira, Giacomo
    Egloff, Ann Marie
    Zeng, Zexiang
    Chernock, Rebecca
    Zhou, Liye
    Messier, Cameron
    Lizotte, Patrick
    Wolff, Jacquelyn
    Pfaff, Kathleen
    Stromhaug, Kari
    Haddad, Robert
    Hanna, Glenn
    Schoenfeld, Jonathan
    Goguen, Laura
    Annino, Donald
    Jo, Vickie
    Oppelt, Peter
    Pipkorn, Patrik
    Jackson, Ryan
    Puram, Sidharth
    Paniello, Randal
    Rich, Jason
    Webb, Jason
    Zevallos, Jose
    Mansour, Mena
    Fu, Jingxin
    Dunn, Gavin
    Rodig, Scott
    Ley, Jessica
    Morris, Luc
    Dunn, Lara
    Paweletz, Cloud
    Kallogjeri, Dorina
    Piccirillo, Jay
    Adkins, Douglas
    Wu, Catherine
    Uppaluri, Ravindra
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A524 - A525
  • [26] Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Greenhalgh, J.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    McLeod, C.
    Dundar, Y.
    Proudlove, C.
    Shaw, R.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 49 - 54
  • [27] Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients
    Lu Li
    Lu Chen
    Lu Yan
    Yueqian Guo
    Fang Li
    Ming Fan
    Mei Lan
    Xin Lai
    Jie Zhou
    Yecai Huang
    Peng Xu
    Jinyi Lang
    Mei Feng
    [J]. Radiation Oncology, 18
  • [28] Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
    Callejas-Valera, Juan L.
    Vermeer, Daniel W.
    Lucido, Christopher T.
    Williamson, Caitlin
    Killian, Marisela
    Vermeer, Paola D.
    Spanos, William C.
    Powell, Steven F.
    [J]. CANCERS, 2022, 14 (10)
  • [29] PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
    Dun-Chang Mo
    Jian-Feng Huang
    Peng-Hui Luo
    Long Chen
    Biao Zou
    Han-Lei Wang
    [J]. European Archives of Oto-Rhino-Laryngology, 2023, 280 : 1 - 9
  • [30] PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
    Mo, Dun-Chang
    Huang, Jian-Feng
    Luo, Peng-Hui
    Chen, Long
    Zou, Biao
    Wang, Han-Lei
    [J]. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (01) : 1 - 9
12345